GZMA Protein (AA 26-262)
-
- Target See all GZMA Proteins
- GZMA (Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated serine Esterase 3) (GZMA))
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 26-262
-
Origin
- Human
-
Source
- HEK-293 Cells
- Application
- Intracellular Flow Cytometry (ICFC)
- Purity
- > 90 % , as determined by Coomassie stained SDS-PAGE.
- Sterility
- 0.22 μm filtered
- Endotoxin Level
-
Less than 1.0 EU per μg of protein as determine by the LAL method.
- Top Product
- Discover our top product GZMA Protein
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Comment
-
Biological activity: Lysyl endopeptidase activated human granzyme A cleaves the peptide substrate N-carbobenzyloxy-Gly-Arg-ThioBenzyl ester (Z-GR-SBzl), in the presence of 5,5'Dithio-bis (2-nitrobenzoic acid) (DTNB), with an activity >5,000 pmol/min/μg.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Reconstitution
- For maximum results, quick spin vial prior to opening.
- Buffer
- 0.22 μm filtered protein solution is in PBS, pH 7.4.
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Unopened vial can be stored at -70°C for six months.
-
- Target
- GZMA (Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated serine Esterase 3) (GZMA))
- Alternative Name
- Granzyme A (GZMA Products)
- Synonyms
- gzmA Protein, GZMA Protein, AW494114 Protein, Ctla-3 Protein, Ctla3 Protein, Hf Protein, SE1 Protein, TSP-1 Protein, TSP1 Protein, CTLA3 Protein, HFSP Protein, granzyme A Protein, Granzyme A Protein, granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Protein, gzmA Protein, GZMA Protein, graa Protein, Gzma Protein
- Background
- Granzyme A is a serine protease belonging to the granzyme family and is expressed exclusively by cytotoxic T cells (CTL) and NK cells. Most circulating CD56+CD8- NK cells, and approximately half of circulating CD8+ T cells, coexpress both granzymes A and B. In contrast, few circulating CD4+ T cells express granzyme A or B. Activation of CD8+ and CD4+ T lymphocytes induces substantial expression of granzyme B, but not granzyme A. Following receptor-mediated conjugate formation between a granzyme-containing cell and an infected or transformed target cell, granzymes enter the target cell via endocytosis and induce apoptosis. Granzyme A was found to induce caspase independent cell death when it enters into the target cell by perforin. Once in a cell, granzyme A activates DNA nicking by DNAse NM23-H1, a tumor suppressor gene product whose expression is reduced in transformed, metastatic cells. Dysregulation of this pathway results in several human diseases, such as hemophagocytic lymphohistiocytosis. Besides the protease activity, granzyme A induces human lung fibroblasts to produce IL-6 and IL-8. Cytokine induction is abrogated by treating the serine protease with the suicide serine protease inhibitor 3,4-dichloroisocoumarin. Other fibroblast lines, as well as epithelial cells, produce cytokines in response to granzyme A. These findings suggest that granzyme A can function as an activation molecule with potentially important immunoregulatory functions. However, CTLs from mice lacking granzyme A induce morphologically normal apoptosis in vitro, but those from mice that are deficient of granzyme B induce the nuclear features of apoptosis (particularly DNA fragmentation) more slowly than do wild-type CTLs.
- Molecular Weight
- This 252 amino acid recombinant protein has a predicted molecular mass of approximately 28 kDa. The protein migrates at about 35 kDa in DTT-reducing conditions and about 55 kDa in non-reducing conditions by SDS-PAGE.The predicted N-terminal amino acid is
- Pathways
- Apoptosis
-